Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Translational Stroke Research
Published in: Translational Stroke Research 4/2017

01-08-2017 | Editorial

Translational Stroke Research Opportunities and a Strategy to Develop Effective Cytoprotection

Author: Paul A. Lapchak

Published in: Translational Stroke Research | Issue 4/2017

Login to get access

Excerpt

The recent success of endovascular procedures alone or accompanied by thrombolysis has provided stroke victims with a form of therapy that can be used in a population of stroke victims with large vessel occlusions (see [1‐6]. And (MR. CLEAN) [7], Endovascular Treatment for Small Core and Proximal Occlusion Ischemic Stroke (ESCAPE) [8], Endovascular Revascularization With Solitaire Device Versus Best Medical Therapy in Anterior Circulation Stroke Within 8 Hours (REVASCAT) [9], Solitaire With the Intention For Thrombectomy as PRIMary Endovascular Treatment (SWIFT PRIME) Trial [10] and Extending the Time for Thrombolysis in Emergency Neurological Deficits-Intra-Arterial (EXTEND-IA) [11]). The immediate goal of the stroke community is to continue to develop novel forms of cytoprotective therapy to further enhance the benefit of embolectomy and thrombolysis [12‐14]. By demonstrating additional clinical benefit with a cytoprotective compound in standardized translational stroke models, we may be able to initiate clinical trials in patients undergoing thrombolytic/endovascular procedures [12, 15]. However, the development of neuroprotective compounds has been fraught with problems, in particular, the lack of efficacy in many stroke clinical trials. There are many reasons for this failure, and they have been reviewed in detail elsewhere [12, 16‐18]. …
Literature
1.
Berkhemer OA, Fransen PS, Beumer D, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med. 2015;372(1):11–20.CrossRefPubMed
2.
Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015;372(11):1019–30.CrossRefPubMed
3.
Campbell BC, Mitchell PJ, Kleinig TJ, Dewey HM, Churilov L, Yassi N, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med. 2015;372(11):1009–18.CrossRefPubMed
4.
Jovin TG, Chamorro A, Cobo E, de Miquel MA, Molina CA, Rovira A, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med. 2015;372(24):2296–306.CrossRefPubMed
5.
Saver JL, Goyal M, Bonafe A, Diener HC, Levy EI, Pereira VM, et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med. 2015;372(24):2285–95.CrossRefPubMed
6.
Rebello LC, Haussen DC, Grossberg JA, Belagaje S, Lima A, Anderson A, et al. Early endovascular treatment in intravenous tissue plasminogen activator-ineligible patients. Stroke. 2016;47(4):1131–4.CrossRefPubMed
7.
8.
9.
10.
11.
12.
Lapchak PA. Critical early thrombolytic and endovascular reperfusion therapy for acute ischemic stroke victims: a call for adjunct neuroprotection. Transl Stroke Res. 2015a;6(5):345–54.CrossRefPubMedPubMedCentral
13.
Linfante I, Cipolla MJ. Improving reperfusion therapies in the era of mechanical thrombectomy. Transl Stroke Res. 2016;7(4):294–302.CrossRefPubMed
14.
Henninger N, Fisher M. Extending the time window for endovascular and pharmacological reperfusion. Transl Stroke Res. 2016;7(4):284–93.CrossRefPubMed
15.
Goyal M, Menon BK, van Zwam WH, Dippel DW, Mitchell PJ, Demchuk AM, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet. 2016;387(10029):1723–31.CrossRefPubMed
16.
O’Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW. 1,026 experimental treatments in acute stroke. Ann Neurol. 2006;59(3):467–77.CrossRefPubMed
17.
Lapchak PA. A cost-effective rabbit embolic stroke bioassay: insight into the development of acute ischemic stroke therapy. Transl Stroke Res. 2015b;6(2):99–103.CrossRefPubMedPubMedCentral
18.
Dirnagl U. Thomas Willis lecture: is translational stroke research broken, and if so, how can we fix it? Stroke. 2016;47(8):2148–53.CrossRefPubMed
19.
20.
STAIR Therapy Academic Industry Roundtable (STAIR). Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke. 1999;30(12):2752–8.
21.
Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW, et al. A call for transparent reporting to optimize the predictive value of preclinical research. Nature. 2012;490(7419):187–91.CrossRefPubMedPubMedCentral
22.
23.
Lapchak PA. Recommendations and practices to optimize stroke therapy: developing effective translational research programs. Stroke. 2013;44(3):841–3.CrossRefPubMed
24.
Lapchak PA, Zhang JH, Noble-Haeusslein LJ. RIGOR guidelines: escalating STAIR and STEPS for effective translational research. Transl Stroke Res. 2013;4(3):279–85.CrossRefPubMed
25.
Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, National Centre for the Replacement R, et al. Animal research: reporting in vivo experiments--the ARRIVE guidelines. J Cereb Blood Flow Metab. 2011;31(4):991-3
26.
Hirst JA, Howick J, Aronson JK, Roberts N, Perera R, Koshiaris C, et al. The need for randomization in animal trials: an overview of systematic reviews. PLoS One. 2014;9(6):e98856.CrossRefPubMedPubMedCentral
27.
Lapchak PA. Translational stroke research using a rabbit embolic stroke model: a correlative analysis hypothesis for novel therapy development. Translational Stroke Research. 2010;1(2):96–107.CrossRefPubMedPubMedCentral
28.
Lapchak PA. A clinically relevant rabbit embolic stroke model for acute ischemic stroke therapy development: mechanisms and targets. In: Lapchak PA, Zhang JH, editors. Translational stroke research: from target selection to clinical trials. USA: Springer; 2011.
29.
Macleod MR, Fisher M, O'Collins V, Sena ES, Dirnagl U, Bath PM, et al. Good laboratory practice: preventing introduction of bias at the bench. Stroke. 2009;40(3):e50-2. Macleod MR, Fisher M, O'Collins V, Sena ES, Dirnagl U, Bath PM, et al. Good laboratory practice: preventing introduction of bias at the bench. Stroke. 2009;40(3):e50-2.
30.
31.
32.
Ergul A, Hafez S, Fouda A, Fagan SC. Impact of comorbidities on acute injury and recovery in preclinical stroke research: focus on hypertension and diabetes. Transl Stroke Res. 2016;7(4):248–60.CrossRefPubMed
33.
Ahnstedt H, McCullough LD, Cipolla MJ. The importance of considering sex differences in translational stroke research. Transl Stroke Res. 2016;7(4):261–73.CrossRefPubMed
34.
35.
Zivin JA, Fisher M, DeGirolami U, Hemenway CC, Stashak JA. Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science. 1985;230(4731):1289.CrossRefPubMed
36.
Cook DJ, Teves L, Tymianski M. Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain. Nature. 2012a;483(7388):213–7.CrossRefPubMed
37.
Cook DJ, Teves L, Tymianski M. A translational paradigm for the preclinical evaluation of the stroke neuroprotectant Tat-NR2B9c in gyrencephalic nonhuman primates. Sci Transl Med. 2012b;4(154):154ra33.CrossRef
Metadata
Title
Translational Stroke Research Opportunities and a Strategy to Develop Effective Cytoprotection
Author
Paul A. Lapchak
Publication date
01-08-2017
Publisher
Springer US
Published in
Translational Stroke Research / Issue 4/2017
Print ISSN: 1868-4483
Electronic ISSN: 1868-601X
DOI
https://doi.org/10.1007/s12975-017-0529-3

Other articles of this Issue 4/2017

Translational Stroke Research 4/2017 Go to the issue

Original Article

MiR-126 Affects Brain-Heart Interaction after Cerebral Ischemic Stroke

Original Article

Spontaneous Recovery of Upper Extremity Motor Impairment After Ischemic Stroke: Implications for Stem Cell-Based Therapeutic Approaches

Original Article

Preclinical Development of a Prophylactic Neuroprotective Therapy for the Preventive Treatment of Anticipated Ischemia-Reperfusion Injury

Original Article

Evidence for Decreased Brain Parenchymal Volume After Large Intracerebral Hemorrhages: a Potential Mechanism Limiting Intracranial Pressure Rises

Short Communication

Task-Specific Motor Rehabilitation Therapy After Stroke Improves Performance in a Different Motor Task: Translational Evidence

Original Article

Sodium Tanshinone IIA Sulfonate Enhances Effectiveness Rt-PA Treatment in Acute Ischemic Stroke Patients Associated with Ameliorating Blood-Brain Barrier Damage